(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 4.53% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Amphastar Pharmaceuticals's revenue in 2026 is $723,305,000.On average, 8 Wall Street analysts forecast AMPH's revenue for 2026 to be $35,829,369,590, with the lowest AMPH revenue forecast at $32,725,759,758, and the highest AMPH revenue forecast at $38,633,830,769. On average, 7 Wall Street analysts forecast AMPH's revenue for 2027 to be $37,143,601,766, with the lowest AMPH revenue forecast at $33,639,748,498, and the highest AMPH revenue forecast at $40,240,318,772.
In 2028, AMPH is forecast to generate $37,778,201,289 in revenue, with the lowest revenue forecast at $33,594,715,368 and the highest revenue forecast at $41,784,311,818.